TY - JOUR T1 - Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at the time of diagnosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA4666 VL - 54 IS - suppl 63 SP - PA4666 AU - Attila Nagy AU - Abigel Kolonics-Farkas AU - Noemi Eszes AU - Krisztina Vincze AU - Veronika Muller Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA4666.abstract N2 - Pulmonary malignancy is one of the most frequent and fatal cancers in older age patients. Infections influence tumor genesis and anticancer therapy in several organs. As data on lower respiratory tract infection (LRTI) and lung cancer outcome are scarce our objective was to determine potential role of LRTI on one-year mortality and its effect on therapeutic possibilities in patients with pulmonary malignancies. All patients diagnosed in 2017 who had bronchoscopic microbial sampling at the time of lung cancer diagnosis (N=143) were included. Group 1 (LRTI+) included patients with confirmed LRTI (N=74) and Group 2 (LRTI-) with no infection (N=69). Clinical characteristics, pathogen profile and one-year survival was analyzed. Age, gender, TNM, stage, histology type, comorbidities or underlying lung disease did not differ among groups. Performance status 0 was significantly less common in Group 1 (LRTI+), while significantly increased neutrophil/lymphocyte ratio was observed. Most common LRTI pathogens included aerobic (N=49), anaerobic (N=14) and fungal (N=26) infections. Chemo/immune/target therapy alone or in combination with radiotherapy were significantly less common in Group 1 (LRTI+) and more patients were only eligible for palliative care. Group 1 patients with LRTI of multiple pathogens compared to single pathogen infection were significantly older, had less frequently adenocarcinoma and had worse performance status. One-year median survival for all patients was 274 days (235 vs. 305 days Group 1 vs Group 2). LRTI is associated with lower one-year median survival of pulmonary malignancy patients, especially in patients with multiple pathogen infections.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4666.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -